Abstract: Improved strainer members for use with pump assemblies and/or fluid systems (e.g., fluid circulation systems) are provided. The present disclosure provides for advantageous strainer members that strain and/or filter fluids in fluid systems (e.g., recreational bodies of water). More particularly, the present disclosure provides for strainer members (e.g., strainer baskets) that include features that improve performance characteristics. Strainer members with an improved ability to resist degradation of pump hydraulic performance when loaded with debris, and/or an improved ability to remove air pockets trapped under the strainer cover at low flow rates are disclosed.

Abstract: Exemplary embodiments include a unitary pool filter tank and/or an underdrain for a pool filter unit. Embodiments of the unitary pool filter tank can have an integrally formed housing and base. The filter tank can be formed using a blow molding process in which the base of the filter tank is reinforced using multiple polymer layers that have been folded and/or pinched together. Embodiments of the underdrain can be formed by interlocking top and bottom components. The top and bottom components can be interlocked by inter-component locking structures.

Abstract: Exemplary embodiments include a unitary pool filter tank and/or an underdrain for a pool filter unit. Embodiments of the unitary pool filter tank can have an integrally formed housing and base. The filter tank can be formed using a blow molding process in which the base of the filter tank is includes a support section and a punted section that has an underdrain mounting member. Embodiments of the underdrain can be formed by interlocking top and bottom components. The top and bottom components can be interlocked by inter-component locking structures.

Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, where R1 is a (C1-C6)alkyl or (C3-C6)cycloalkyl group; R2 is a (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkenyl, (C1-C6)fluoroalkyl, (C1-C3)fluoroalkoxy, or (C1-C6)alkoxy(C1-C6)alkyl group, substituted: (i) with one to three hydroxyl groups, or (ii) with an NRaRb group, where Ra and Rb are independently a hydrogen atom or a (C1-C3)alkyl group; or a pyrrolidinylmethyl group substituted with one to three hydroxyl groups; R9 is the same as R2 or hydrogen; the R2 and R9 groups independently being substitutable with an —OCOR3 group, where R3 is a natural or unnatural amino acid derivative or a piperidyl group; alternatively, R2 and R9 together form a heterocyclic compound; X and Y are independently a substitutable phenyl or heteroaryl group, the heteroaryl group being a thienyl, pyridyl, pyrimidinyl, thiazolyl, pyrrolyl, or furanyl group; and R6 is a hydrogen or a (C1-C3)alkyl group.

Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumours (IMT) and non-small cell lung cancer (NSCLC).

Abstract: The invention relates to pyrrolo[2,3-b]pyridine compounds and azaindole compounds used for the synthesis thereof. The invention also relates to methods for the production thereof and the uses thereof. Said novel pyrrolo[2,3-b]pyridine compounds according to the invention have great antiproliferative, apoptotic, and neuroprotective activities. The invention particularly applies to the pharmaceutical field.

Abstract: The invention relates to novel derivatives capable of increasing the synthesis and/or the release of neurotrophic factors, and therefore able to be used as a human or veterinary medicinal product. The invention also relates to methods for preparing the derivatives and also to the intermediates required for their synthesis.

Abstract: A non-cytotoxic pharmaceutical composition acting on the proliferation of clonogenic cells in malignant tumors and including an efficient amount of a compound selected among the compounds of formula (I) and (Ia).

Abstract: The invention concerns a pharmaceutical composition having an activity on the proliferation of clonogenic cells in tumours and comprising an efficient amount of a compound selected among the compounds of formulae (I) and (Ia) wherein: X, R1, R2, R3, R4, R5, R6 are as defined in claim 1.

Abstract: This invention deals with an adaptive echo cancelling system for communication networks. The system includes an adaptive filter for acoustic echo cancellation that uses a combination of echo cancelling and gain control techniques. The main advantages of the combination of these approaches are good communication quality during double talk and easier control of the output echo level.

Abstract: The method of the invention, to produce a polysaccharide of the xanthane type, makes use of a strain of Xanthemonas, notably of the strain no. ATCC 31 176 deposited on Oct. 14, 1975, which is cultivated on a medium with 5 to 55 g/l or more of carbohydrates and comprising at least one amino-acid selected from glutamic acid, glutamine, arginine, tyrosine, threonine, aspartic acid, asparagine, proline, leucine tryptophane and other amino-acids giving a production of polysaccharide at least equal to 50% of that yielded by corn steep liquor, the total nitrogen of said medium being 0.1 g/l to 5 g/1; the fermentation is carried out at 25.degree.-35.degree. C under aerobiosis.